USD10
AVIR acciones
Acerca de Atea PharmaceuticalsAtea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
USD10
AVIR acciones
Acerca de Atea PharmaceuticalsAtea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
Estadísticas
VENTANA DE OPERACIÓN
Abierta
CIERRA A LAS
20:00 GMT+0
CAPITALIZACIÓN DE MERCADO
417,48 M US$
PRECIO DE APERTURA
5,52 US$
BAJO (1Y)
2,46 US$
ALTO (1Y)
6,45 US$
BAJO (24H)
5,20 US$
Alza (24H)
5,54 US$
Volumen (24 h)
221,72 mil US$